Literature DB >> 11404820

Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma.

D Astuti1, F Latif, A Dallol, P L Dahia, F Douglas, E George, F Sköldberg, E S Husebye, C Eng, E R Maher.   

Abstract

The pheochromocytomas are an important cause of secondary hypertension. Although pheochromocytoma susceptibility may be associated with germline mutations in the tumor-suppressor genes VHL and NF1 and in the proto-oncogene RET, the genetic basis for most cases of nonsyndromic familial pheochromocytoma is unknown. Recently, pheochromocytoma susceptibility has been associated with germline SDHD mutations. Germline SDHD mutations were originally described in hereditary paraganglioma, a dominantly inherited disorder characterized by vascular tumors in the head and the neck, most frequently at the carotid bifurcation. The gene products of two components of succinate dehydrogenase, SDHC and SDHD, anchor the gene products of two other components, SDHA and SDHB, which form the catalytic core, to the inner-mitochondrial membrane. Although mutations in SDHC and in SDHD may cause hereditary paraganglioma, germline SDHA mutations are associated with juvenile encephalopathy, and the phenotypic consequences of SDHB mutations have not been defined. To investigate the genetic causes of pheochromocytoma, we analyzed SDHB and SDHC, in familial and in sporadic cases. Inactivating SDHB mutations were detected in two of the five kindreds with familial pheochromocytoma, two of the three kindreds with pheochromocytoma and paraganglioma susceptibility, and 1 of the 24 cases of sporadic pheochromocytoma. These findings extend the link between mitochondrial dysfunction and tumorigenesis and suggest that germline SDHB mutations are an important cause of pheochromocytoma susceptibility.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11404820      PMCID: PMC1226047          DOI: 10.1086/321282

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  25 in total

1.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma.

Authors:  B E Baysal; R E Ferrell; J E Willett-Brozick; E C Lawrence; D Myssiorek; A Bosch; A van der Mey; P E Taschner; W S Rubinstein; E N Myers; C W Richard; C J Cornelisse; P Devilee; B Devlin
Journal:  Science       Date:  2000-02-04       Impact factor: 47.728

2.  Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.

Authors:  M E Cockman; N Masson; D R Mole; P Jaakkola; G W Chang; S C Clifford; E R Maher; C W Pugh; P J Ratcliffe; P H Maxwell
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

Review 3.  Mitochondria and apoptosis.

Authors:  D R Green; J C Reed
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

4.  Compound heterozygous mutations in the flavoprotein gene of the respiratory chain complex II in a patient with Leigh syndrome.

Authors:  B Parfait; D Chretien; A Rötig; C Marsac; A Munnich; P Rustin
Journal:  Hum Genet       Date:  2000-02       Impact factor: 4.132

5.  Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.

Authors:  M Ohh; C W Park; M Ivan; M A Hoffman; T Y Kim; L E Huang; N Pavletich; V Chau; W G Kaelin
Journal:  Nat Cell Biol       Date:  2000-07       Impact factor: 28.824

6.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

7.  A family with hereditary extra-adrenal paragangliomas without evidence for mutations in the von Hippel-Lindau disease or ret genes.

Authors:  F Sköldberg; L Grimelius; E R Woodward; F Rorsman; E W Van Schothorst; O Winqvist; F A Karlsson; G Akerström; O Kämpe; E S Husebye
Journal:  Clin Endocrinol (Oxf)       Date:  1998-01       Impact factor: 3.478

8.  Frequent allelic imbalance suggests involvement of a tumor suppressor gene at 1p36 in the pathogenesis of human lung cancers.

Authors:  S Nomoto; N Haruki; Y Tatematsu; H Konishi; T Mitsudomi; T Takahashi; T Takahashi
Journal:  Genes Chromosomes Cancer       Date:  2000-07       Impact factor: 5.006

Review 9.  The VHL tumour-suppressor gene paradigm.

Authors:  W G Kaelin; E R Maher
Journal:  Trends Genet       Date:  1998-10       Impact factor: 11.639

Review 10.  Mutagenesis, tumorigenicity, and apoptosis: are the mitochondria involved?

Authors:  L R Cavalli; B C Liang
Journal:  Mutat Res       Date:  1998-02-26       Impact factor: 2.433

View more
  326 in total

1.  Integrative epigenomic and genomic analysis of malignant pheochromocytoma.

Authors:  Johanna Sandgren; Robin Andersson; Alvaro Rada-Iglesias; Stefan Enroth; Goran Akerstrom; Jan P Dumanski; Jan Komorowski; Gunnar Westin; Claes Wadelius
Journal:  Exp Mol Med       Date:  2010-07-31       Impact factor: 8.718

2.  Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2.

Authors:  Ronen Spiegel; Ophry Pines; Asaf Ta-Shma; Efrat Burak; Avraham Shaag; Jonatan Halvardson; Shimon Edvardson; Muhammad Mahajna; Shamir Zenvirt; Ann Saada; Stavit Shalev; Lars Feuk; Orly Elpeleg
Journal:  Am J Hum Genet       Date:  2012-03-09       Impact factor: 11.025

3.  Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations.

Authors:  Joanne Ngeow; Jessica Mester; Lisa A Rybicki; Ying Ni; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

4.  Role of SDHAF2 and SDHD in von Hippel-Lindau associated pheochromocytomas.

Authors:  Johan Kugelberg; Jenny Welander; Francesca Schiavi; Ambrogio Fassina; Martin Bäckdahl; Catharina Larsson; Giuseppe Opocher; Peter Söderkvist; Patricia L Dahia; Hartmut P H Neumann; Oliver Gimm
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

Review 5.  New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.

Authors:  David Taïeb; Karel Pacak
Journal:  Trends Endocrinol Metab       Date:  2017-08-31       Impact factor: 12.015

6.  Diagnosis and management of hereditary paraganglioma syndrome due to the F933>X67 SDHD mutation.

Authors:  Monica L Marvin; Carol R Bradford; James C Sisson; Stephen B Gruber
Journal:  Head Neck       Date:  2009-05       Impact factor: 3.147

7.  Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior.

Authors:  Hans K Ghayee; Bas Havekes; Eleonora P M Corssmit; Graeme Eisenhofer; Stephen R Hammes; Zahid Ahmad; Alexander Tessnow; Ivica Lazúrová; Karen T Adams; Antonio T Fojo; Karel Pacak; Richard J Auchus
Journal:  Endocr Relat Cancer       Date:  2008-12-15       Impact factor: 5.678

8.  Multi-institutional survey of carotid body tumors in Japan.

Authors:  Aya Ikeda; Kiyoto Shiga; Katsunori Katagiri; Daisuke Saito; Jun Miyaguchi; Shin-Ichi Oikawa; Kodai Tsuchida; Takahiro Asakage; Hiroyuki Ozawa; Ken-Ichi Nibu; Naoki Ohtsuki; Yasushi Fujimoto; Ken-Ichi Kaneko
Journal:  Oncol Lett       Date:  2018-02-02       Impact factor: 2.967

Review 9.  The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors.

Authors:  Paraskevi Xekouki; Ana Brennand; Ben Whitelaw; Karel Pacak; Constantine A Stratakis
Journal:  Horm Metab Res       Date:  2018-10-01       Impact factor: 2.936

10.  The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway.

Authors:  A P Gimenez-Roqueplo; J Favier; P Rustin; J J Mourad; P F Plouin; P Corvol; A Rötig; X Jeunemaitre
Journal:  Am J Hum Genet       Date:  2001-10-16       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.